BiotechTube

Apatinib+IE + IE

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Effect of Drug

Conditions

Effect of Drug, Drug, Toxicity

Trial Timeline

Mar 1, 2022 → Nov 26, 2023

NCT ID
NCT05277480

About Apatinib+IE + IE

Apatinib+IE + IE is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Effect of Drug. The current trial status is completed. This product is registered under clinical trial identifier NCT05277480. Target conditions include Effect of Drug, Drug, Toxicity.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05277480Phase 2Completed

Competing Products

20 competing products in Effect of Drug

See all competitors
ProductCompanyStageHype Score
ORIN1001Fosun PharmaPhase 1/2
40
GP404141 + NplateGEROPHARMPhase 3
69
Milademetan Treatment A + Milademetan Treatment B + Milademetan Treatment CDaiichi SankyoPhase 1
33
E7386EisaiPhase 1
33
Duloxetine + WarfarinEli LillyPhase 1
33
Budesonide NasalJohnson & JohnsonApproved
85
SHR-1603Jiangsu Hengrui MedicinePhase 1
33
Famitinib + Ifosfamide + CamrelizumabJiangsu Hengrui MedicinePhase 1/2
41
AZD7986, oral solution, 1 to 50 mg/mL + Placebo, oral solutionAstraZenecaPhase 1
33
AZD6482 + Clopidogrel + ASAAstraZenecaPhase 1
33
Albuterol Sulfate + Nicardipine Hydrochloride + Dobutamine Hydrochloride + Phenylephrine Hydrochloride + Verapamil Hydrochloride + Phentolamine Mesylate + PlaceboAstraZenecaPhase 1
33
esomeprazole/ASA Fixed Dose Combination (FDC)AstraZenecaPhase 1
33
AZD6482 + PlaceboAstraZenecaPhase 1
33
MSC2156119JMerckPhase 1
33
Docetaxel + PembrolizumabMerckPhase 2
52
daptomycinMerckPhase 3
77
Cyclosporine & Cellcept + Prograf & Cellcept + Low Dose CNI (Cyclosporine or FK) and Cellcept + Rapamune and CellceptRochePhase 1/2
41
EvolocumabAmgenPhase 1
32
GS-0976 + PlaceboGilead SciencesPhase 1
32
Varenicline (Champix)PfizerPhase 1
32

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85